Storia in 3 fonti

First Major Trial Win for Contemporary DOACs in Lower-Risk Afib

SINGLE-AF trial shows cardiovascular protection without unacceptable bleeding

Raccontata da

healio.com

medpagetoday.com

medicalxpress.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 g fa

First Major Trial Win for Contemporary DOACs in Lower-Risk Afib

SINGLE-AF trial shows cardiovascular protection without unacceptable bleeding

originale

healio.com2 g fa

Anticoagulation benefits patients with atrial fibrillation, intermediate stroke risk

MUNICH — In patients with atrial fibrillation and intermediate risk for stroke, direct oral anticoagulants were linked to reduced risk for death, stroke and major bleeding compared with no anticoagulation, researchers…

Leggi questa versione → originale

Timeline cronologica

venerdì 28 agosto 2026·healio.com
Anticoagulation benefits patients with atrial fibrillation, intermediate stroke risk
MUNICH — In patients with atrial fibrillation and intermediate risk for stroke, direct oral anticoagulants were linked to reduced risk for death, stroke and major bleeding…
venerdì 28 agosto 2026·medpagetoday.com
First Major Trial Win for Contemporary DOACs in Lower-Risk Afib
SINGLE-AF trial shows cardiovascular protection without unacceptable bleeding

First Major Trial Win for Contemporary DOACs in Lower-Risk Afib

Confronto fonti

First Major Trial Win for Contemporary DOACs in Lower-Risk Afib

Anticoagulation benefits patients with atrial fibrillation, intermediate stroke risk

Timeline cronologica

Anticoagulation benefits patients with atrial fibrillation, intermediate stroke risk

First Major Trial Win for Contemporary DOACs in Lower-Risk Afib

People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical…

People with atrial fibrillation at intermediate risk of stroke benefit from oral anticoagulants, clinical trial finds